Hereditary papillary renal carcinoma type I

被引:69
作者
Dharmawardana, PG [1 ]
Giubellino, A [1 ]
Bottaro, DP [1 ]
机构
[1] NCI, Ctr Canc Res, Urol Oncol Branch, NIH, Bethesda, MD 20892 USA
关键词
c-Met; HGF/SF; HPRC; missense mutations; renal carcinoma;
D O I
10.2174/1566524043359674
中图分类号
R-3 [医学研究方法]; R3 [基础医学];
学科分类号
1001 ;
摘要
Germline missense mutations in the tyrosine kinase domain of the hepatocyte growth factor/scatter factor (HGF/SF) receptor, c-Met, are thought to be responsible for hereditary papillary renal carcinoma (HPRC) type 1, a form of human kidney cancer. In addition to extensive linkage analysis of HPRC families localizing the HPRC type 1 gene within chromosome 7, the demonstration that individual c-Met mutations reconstituted in cultured cells display enhanced and dysregulated kinase activity, and confer cell transformation and tumorigenicity in mice, solidifies this conclusion. Our prior knowledge of HGF/SF biology and c-Met signaling enabled rapid progress in unraveling the molecular pathogenesis of HPRC type 1, and in laying the framework for the development of novel therapeutics for the treatment of this cancer. At the same time, the study of HPRC type 1 has refined our appreciation of the oncogenic potential of c-Met signaling, and challenges our current understanding of HGF/SF and c-Met function in health and disease.
引用
收藏
页码:855 / 868
页数:14
相关论文
共 112 条
[61]   Increase in hepatocyte growth factor receptor tyrosine kinase activity in renal carcinoma cells is associated with increased motility partly through phosphoinositide 3-kinase activation [J].
Nakamura, T ;
Kanda, S ;
Yamamoto, K ;
Kohno, T ;
Maeda, K ;
Matsuyama, T ;
Kanetake, H .
ONCOGENE, 2001, 20 (52) :7610-7623
[62]   Myocardial protection from ischemia/reperfusion injury by endogenous and exogenous HGF [J].
Nakamura, T ;
Mizuno, S ;
Matsumoto, K ;
Sawa, Y ;
Matsuda, H ;
Nakamura, T .
JOURNAL OF CLINICAL INVESTIGATION, 2000, 106 (12) :1511-1519
[63]  
Olivero M, 1999, INT J CANCER, V82, P640, DOI 10.1002/(SICI)1097-0215(19990827)82:5<640::AID-IJC4>3.0.CO
[64]  
2-6
[65]   CD44 is required for two consecutive steps in HGF/c-Met signaling [J].
Orian-Rousseau, V ;
Chen, LF ;
Sleeman, JP ;
Herrlich, P ;
Ponta, H .
GENES & DEVELOPMENT, 2002, 16 (23) :3074-3086
[66]   EGFR mutations in lung cancer:: Correlation with clinical response to gefitinib therapy [J].
Paez, JG ;
Jänne, PA ;
Lee, JC ;
Tracy, S ;
Greulich, H ;
Gabriel, S ;
Herman, P ;
Kaye, FJ ;
Lindeman, N ;
Boggon, TJ ;
Naoki, K ;
Sasaki, H ;
Fujii, Y ;
Eck, MJ ;
Sellers, WR ;
Johnson, BE ;
Meyerson, M .
SCIENCE, 2004, 304 (5676) :1497-1500
[67]  
Park WS, 1999, CANCER RES, V59, P307
[68]   Signaling through scaffold, anchoring, and adaptor proteins [J].
Pawson, T ;
Scott, JD .
SCIENCE, 1997, 278 (5346) :2075-2080
[69]   Hypoxia promotes invasive growth by transcriptional activation of the met protooncogene [J].
Pennacchietti, S ;
Michieli, P ;
Galluzzo, M ;
Mazzone, M ;
Giordano, S ;
Comoglio, PM .
CANCER CELL, 2003, 3 (04) :347-361
[70]   A conserved DpYR motif in the juxtamembrane domain of the Met receptor family forms an atypical c-Cbl/Cbl-b tyrosine kinase binding domain binding site required for suppression of oncogenic activation [J].
Peschard, P ;
Ishiyama, N ;
Lin, T ;
Lipkowitz, S ;
Park, M .
JOURNAL OF BIOLOGICAL CHEMISTRY, 2004, 279 (28) :29565-29571